Disrupting established tumor blood vessels: An emerging therapeutic strategy for cancer
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The unique characteristics of tumor vasculature represent an attractive target that may be exploited by vascular‐targeting anticancer agents. A promising strategy involves the selective disruption of established tumor blood vessels by tumor‐vascular disrupting agents (tumor‐VDAs), which exhibit antivascular activity, resulting in inhibition of tumor blood flow and extensive necrosis within the tumor core. The tumor‐VDA class can be subdivided into flavonoid compounds, which are related to flavone acetic acid, and tubulin‐binding compounds. ASA404, of the flavonoid class, is the most advanced tumor‐VDA in clinical development and has been evaluated preclinically and in several phase 1 and phase 2 studies. Preclinical studies have demonstrated the selective apoptosis of tumor endothelial cells and the inhibition of tumor blood flow. Synergistic activity was observed with ASA404 and with several chemotherapeutic agents, particularly taxanes. In clinical trials, compared with chemotherapy alone, ASA404 was tolerated well and produced improved activity in patients with nonsmall cell lung cancer when combined with paclitaxel and carboplatin. Phase 3 clinical trials are ongoing. Selectively targeting established tumor vasculature with tumor‐VDAs represents a promising and innovative approach to improving the efficacy of standard anticancer therapies. Cancer 2010. © 2010 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Abnormalities of Basement Membrane on Blood Vessels and Endothelial Sprouts in Tumors
Baluk, P., Morikawa, S., Haskell, A., Mancuso, M., & McDonald, D. M. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63540-7 · Cited by 528
Cited by
Siemann, D. W. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.001 · Cited by 611
Lara, P. N., Douillard, J.-Y., Nakagawa, K., von Pawel, J., McKeage, M. J., Albert, I., Losonczy, G., Reck, M., Heo, D.-S., Fan, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0660 · Cited by 323
Self-citationAn overview on Vadimezan (DMXAA): The vascular disrupting agent
Daei Farshchi Adli, A., Jahanban‐Esfahlan, R., Seidi, K., Samandari‐Rad, S., & Zarghami, N. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13166 · Cited by 125
Tumor vascular infarction: prospects and challenges
Jahanban-Esfahlan, R., Seidi, K., & Zarghami, N. (2017) · International Journal of Hematology · doi:10.1007/s12185-016-2171-3 · Cited by 88
Combination of nanotechnology with vascular targeting agents for effective cancer therapy
Jahanban‐Esfahlan, R., Seidi, K., Banimohamad‐Shotorbani, B., Jahanban‐Esfahlan, A., & Yousefi, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26051 · Cited by 84
Metadata
- Authors
- McKeage, M. J., & Baguley, B. C.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-04-06
- Volume
- 116
- Issue
- 8
- Pages
- 1859-1871
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2091844981
- Cited by
- 148
- References
- 3
- FWCI
- 8.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Disrupting established tumor blood vessels: An emerging therapeutic strategy for cancer. https://app.cochat.ai/papers/10.1002/cncr.24975
- The paper
- McKeage, M. J., & Baguley, B. C. (2010). Disrupting established tumor blood vessels: An emerging therapeutic strategy for cancer. Cancer. https://doi.org/10.1002/cncr.24975
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.